Imexpharm Past Earnings Performance

Past criteria checks 5/6

Imexpharm has been growing earnings at an average annual rate of 13.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.7% per year. Imexpharm's return on equity is 14.4%, and it has net margins of 12.8%.

Key information

13.7%

Earnings growth rate

12.7%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate8.7%
Return on equity14.4%
Net Margin12.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Imexpharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

HOSE:IMP Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,994,037254,623604,5880
30 Sep 231,943,044258,089610,7050
30 Jun 231,893,973244,173612,3130
31 Mar 231,808,733213,197577,7690
31 Dec 221,643,707196,715523,0550
30 Sep 221,483,063193,294435,5630
30 Jun 221,321,432168,823393,0800
31 Mar 221,284,405176,146373,9750
31 Dec 211,266,597173,513362,8680
30 Sep 211,357,095173,320398,6460
30 Jun 211,390,894192,894404,5110
31 Mar 211,362,172184,242372,3340
31 Dec 201,369,422179,658356,7630
30 Sep 201,398,480164,014380,7310
30 Jun 201,436,011154,636399,0440
31 Mar 201,432,983145,354423,3440
31 Dec 191,402,454142,900436,0160
30 Sep 191,261,051131,865404,6850
30 Jun 191,230,077125,694399,7400
31 Mar 191,204,780124,885408,6090
31 Dec 181,184,818122,041387,1770
30 Sep 181,224,760112,394415,0070
30 Jun 181,178,882106,176402,2240
31 Mar 181,194,327109,745408,6900
31 Dec 171,165,456103,277415,3290
30 Sep 171,116,855110,222442,7380
30 Jun 171,081,387104,160444,4870
31 Mar 171,041,96790,389419,2880
31 Dec 161,010,34688,009372,1320
30 Sep 16979,58775,696231,3410
30 Jun 16948,20870,215209,2750
31 Mar 16941,85778,639261,5290
31 Dec 15964,31981,760265,9380
30 Sep 15935,08581,196326,3940
30 Jun 15968,85384,855362,3800
31 Mar 15937,56176,918305,2630
31 Dec 14897,13672,933310,3560
30 Sep 14825,30553,276285,2420
30 Jun 14809,11051,677273,4470
31 Mar 14830,00755,051278,5910
31 Dec 13841,31660,624290,3060
30 Sep 13863,00073,279288,0100
30 Jun 13862,48375,840292,7040
31 Mar 13830,18776,835279,5800

Quality Earnings: IMP has high quality earnings.

Growing Profit Margin: IMP's current net profit margins (12.8%) are higher than last year (12%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IMP's earnings have grown by 13.7% per year over the past 5 years.

Accelerating Growth: IMP's earnings growth over the past year (29.4%) exceeds its 5-year average (13.7% per year).

Earnings vs Industry: IMP earnings growth over the past year (29.4%) exceeded the Pharmaceuticals industry -3.6%.


Return on Equity

High ROE: IMP's Return on Equity (14.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.